Regeneron in $2.32B deal
Regeneron partners with Parabilis to target 'undruggable' proteins, expanding its research capabilities. The deal is worth $2.32 billion.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.